Absence of residual vein thrombosis after an episode of idiopathic deep vein thrombosis: short-term anticoagulation is safe. the “extended dacus study”
Abstract number: AS-TH-030
Siragusa1 S.M., Malato2 A., Saccullo1 G., Pizzo2 G., Caramazza2 D., Lo Coco2 L., Baiardi3 G., Milio4 G., Pinto4 A.
11Department of Internal Medicine, Hematology, Palermo 22Department of Internal Medicine, Hematology 33Department of Surgery, Vascular Surgery 44Department of Internal Medicine, CardioAngiology, Palermo, Italy
How-to-cite Siragusa SM, Malato A, Saccullo G, Pizzo G, Caramazza D, Lo Coco L, Baiardi G, Milio G, Pinto A. Absence of residual vein thrombosis after an episode of idiopathic deep vein thrombosis: short-term anticoagulation is safe. the “extended dacus study”. Journal of Thrombosis and Haemostasis 2009; Volume 7, Supplement 2: Abstract AS-TH-030
Residual Vein Thrombosis (RVT) is a marker for assessing individual risk for recurrent Deep Vein Thrombosis (DVT) and for tailoring duration of oral anticoagulants (OA). We evaluated the safety of a RVT-based approach (evaluated 3 months after the index DVT) in patients with idiopathic venous thrombosis. Study design. Prospective controlled study with two groups: patients without RVT stopped OA after 3 months while those with RVT continued for at least additional 3 months. Materials and Methods. Consecutive patients with a first episode of idiopathic DVT of the lower limbs. Patients with cancer or known thrombophilia were excluded. Events, classified as recurrent DVT and/or Pulmonary Embolism and/or major and minor bleeding were evaluated; all patients were followed-up for at least 12 months after OA discontinuation. Results. 518 patients were included in the study: in 206 (39.7%) RVT was considered absent (RVT negative group) while the remaining 312 patients constituted the RVT positive group. The duration of follow-up (FU) was 184.7 years for RVT-negative group and 191.3 years for RVT-positive group. The rate and type of events during FU is reported in table. Conclusions. Our investigation shows that in patients without RVT is safe to withhold OA after 3 months. This accounts for at least 30% of the entire DVT population.
Table: Events between RVT Negative and Positive Groups
|Outcomes||RVT negative group|
n = 206
|RVT positive group|
n = 312
|Recurrences, n/total (%)∗||2/206 (0.9)||63/312 (20.2)||<0.0005|
|Recurrences, n/100 person-year (%)||2/184.7 (1.08)||63/191.3 (32.9)||<0.0005|
|Major bleeding, n/total (%)∗∗||0/206||3/312 (0.9)||–|
|Major bleeding, n/100 person-Yr (%)∗∗||0/184.7||3/191.3 (1.5)||–|
|∗After OAT discontinuation, ∗∗During OAT|
Disclosure of interest: none declared.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
| Back to top